PSTI Key Stats
|Revenue (Quarterly YoY Growth)||-51.28%|
|EPS Diluted (TTM)||-0.3797|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-21.92M|
|Gross Profit Margin (Quarterly)||96.84%|
|Profit Margin (Quarterly)||-5005%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- Pluristem Receives Regulatory Approval to Extend its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea noodls Nov 13
- Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today Fool Nov 13
- Pluristem to extend Phase II study of PLX-PAD cells in South Korea Nov 13
- PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Nov 5
- 4 Healthcare Stock Stories to Start Off the Trading Week Nov 4
- Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model Important Milestone Advances Pluristem’s Clinical Development Program for the Treatment of Preeclampsia Using PLX-PAD Cells noodls Nov 4
- Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model GlobeNewswire Nov 4
- Pluristem to Present at Omics Group's 2nd International Conference and Exhibition on Cell & Gene Therapy GlobeNewswire Oct 23
- Pluristem to Present Scientific Poster and Corporate Overview at Stem Cell Meeting on the Mesa GlobeNewswire Oct 15
- Pluristem's Promising GvHD Indication Pits It Against Osiris Oct 7
PSTI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Pluristem Therapeutic is down 12.13% over the last year vs S&P 500 Total Return up 27.09%, United Therapeutics up 73.79%, and Array BioPharma up 25.91%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for PSTI
Pro Strategies Featuring PSTI
Did Pluristem Therapeutic make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.